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Abstract
Objective
Higher selenium level has been hypothesized to have the potential to reduce the risk of car-
diovascular diseases including dyslipidemia. However, results from previous studies are
inconsistent. This study aims to determine the association between selenium level and dys-
lipidemia in elderly Chinese with relatively low selenium status.
Methods
A cross-sectional study of 1859 participants aged 65 or older from four rural counties in
China was conducted. Serum total cholesterol (TC), triglycerides (TG), high density lipopro-
tein-cholesterol (HDLC) and low-density lipoprotein-cholesterol (LDLC), nail selenium con-
centration and APOE genotype were measured in all subjects. The four types of
dyslipidemia were defined as >5.17mmol/L for High-TC, >1.69 mmol/L for High-TG, >3.36
mmol/L for High-LDLC, and <1.04 mmol/L for Low-HDLC according to Chinese Guidelines
on Prevention and Treatment of Dyslipidemia in Adults. Logistic models adjusting for age,
gender, APOE genotype, body mass index, alcohol consumption, smoking, physical activ-
ity, medication use for cardiovascular diseases were used to examine the relationship
between selenium levels and the risk of dyslipidemia.
Results
Mean nail selenium concentration was 0.465μg/gin this sample. Rates for High-TC, High-
LDLC, High-TG, Low-HDLC were 18.13%, 13.23%, 12.21% and 32.76% respectively.
Results from logistic models indicated that higher selenium levels were significantly associ-
ated with higher risk of High-TC, High-LDLC and lower risk of Low-HDLC adjusting for
covariates (p < 0.0001). Compared with the lowest selenium quartile group, participants in
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selenium quartile groups 2, 3 and 4 had significantly higher rates of High-TC, High-LDLC,
High-TG, and lower rate of Low-HDLC adjusting for covariates. No significant association
was observed between selenium level and the risk of High-TG. APOEε4 carriers had higher
rates of High-TC and High-LDLC. There was no interaction between selenium level and
APOE with the rates of dyslipidemia.
Conclusions
Our results suggest long-term selenium exposure level may be associated with the risk of
dyslipidemia in elderly population. Future studies are needed to examine the underlying
mechanism of the association.
Introduction
Selenium (Se) is an essential micronutrient with antioxidant properties and it has been
hypothesized to have the potential to prevent cardiovascular disease (CVD) and other chronic
diseases [1,2]. Experimental studies suggest that selenium supplement may reduce the risk of
CVD [3–7]. However, in population based studies, the relationship between selenium levels
and the prevalence of CVD was inconsistent [8–11]. Recently, more concern has been raised
about possible adverse cardio-metabolic effects of high selenium status on CVD, such as
increased risk of hyperlipidemia [12], which is one of the pathogenetic bases of cardiovascular
diseases.
As a key component of selenoproteins, selenium plays important roles against oxidative
stress, which is also important to lipid metabolism [13]. Animal studies had indicated that
selenium deficiency may modulate lipoprotein metabolism [14–16]. Selenium supplementa-
tion has also been reported to reduce non-HDL cholesterol in a randomized trial of elderly
volunteers [17]. However, results from epidemiological studies have found that higher sele-
nium levels were associated with higher lipid levels [18–22]. Most of these studies were from
developed countries where selenium supplements were common and individuals with high
cholesterol levels were generally treated with lipid lowering medications. Thus the positive
association between selenium and lipid could have resulted from reverse causation that
individuals with hyperlipidemia were more likely to take dietary supplements including
selenium.
The rural elderly Chinese population represents a unique opportunity for studying the
relationship between long-term selenium exposure and the risk of hyperlipidemia. The
rural Chinese are stable, with most living in the same village throughout their entire life.
They also consume food that is locally grown and rarely take dietary supplements. In prelimi-
nary analysis using baseline data of Selenium and Cognitive Decline Study Cohort with a rel-
atively small sample [23], we found a linkage between selenium exposure level and serum
lipid levels [24]. In addition, we reported that carriers of the APOE ε4 allele had significantly
lower selenium levels measured in nail samples than non-carriers after adjusting for other
significant covariates and controlling for estimated dietary selenium intake [25]. In this
paper, we report our findings from a large cross-sectional study on the association between
selenium levels and the risk of dyslipidemia controlling for APOE genotype in this elderly
Chinese sample.
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Materials and Methods
Study Population
Participants(n = 1859) aged 65 or older from four counties in China were included in this
study: 1067 participants were from the original Selenium and Cognitive Decline Study Cohort
enrolled between 2003 and 2005 as described previously [25], and 792 participants were
enrolled between 2010 and 2012. Two sites were from Sichuan Province in southwestern
China, and the other two sites were from Shandong Province in eastern China. The two prov-
inces were selected because each province can identify two sites with differing selenium levels
with similar levels on other trace element levels according to previous study results by a Chi-
nese research group [26].
Ethics Statement
The study was approved by the Indiana University Institutional Review Board and the Institute
for Environmental Health and Related Safety, Chinese Center for Disease Control and Preven-
tion. All participants provided their written informed consent prior to participating in the
study.
SeleniumMeasures
Fingernail samples were collected and stored in clean plastic bags at the time of interview. Fin-
gernail samples were firstly cleaned by ultrasound followed by socking in nitric acid and per-
chloric acid and digested on electric hot plate, then reduced by hydrochloric acid. The
pretreated samples were restored to room temperature, followed by adding potassium ferricya-
nide and hydrochloric acid, and diluted with deionized water to volume (10 mL). The concen-
tration of selenium was determined by atomic fluorescence spectrometer at the wavelength of
196.0 nm.
Serum Lipid Measures
Fasting peripheral blood samples were collected and serum was separated within four hours
during the 2010–2012 survey. All samples were stored in -80°C refrigerator before analysis.
Serum total cholesterol (TC), triglycerides (TG), high density lipoprotein-cholesterol (HDLC)
and low-density lipoprotein-cholesterol (LDLC) were measured using the Roche Diagnostic
Kits by Hitachi Automatic Biochemistry Analyzer 9700. The definitions for four types of dysli-
pidemia were>5.17mmol/L for High-TC,>1.69 mmol/L for High-TG,>3.36 mmol/L for
High-LDLC, and<1.04 mmol/L for Low-HDLC according to Chinese Guidelines on Preven-
tion and Treatment of Dyslipidemia in Adults [27].
APOEGenotyping
Genomic DNA was extracted with Bio Teke Whole Blood DNA Extraction Kits following the
manufacturer’s instructions. Two single-nucleotide polymorphisms (SNPs) at triplet 112
(rs429385) and 158 (rs7412) were determined by the multiplex tetra-primer amplification
refractory mutation system (T-ARMS) PCR reactions according to literature [28]. Participants
were classified into two groups, APOEε4 carriers (ε2/ε4, ε3/ε4, ε4/ε4) and non-carriers (ε2/
ε2, ε3/ε3, ε2/ε3) in the analysis.
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Collection of Other Risk Factors
Information on age, gender ethnicity, alcohol consumption, smoking history, medication use
for cardiovascular diseases, and physical activity were collected by means of a questionnaire.
All participants in this study are ethnically Han Chinese. Physical activity was classified into
three categories of low, moderate or high according to the Guidelines for Data Processing and
Analysis of the International Physical Activity Questionnaire (IPAQ) [29]. Height and weight
were measured during interview. Body mass index (BMI) was calculated as weight in kilogram
divided by height in square meters.
Statistical Analysis
Descriptive data are expressed as means and standard deviation, percentages or percentiles. To
better capture the association between selenium levels and lipid biomarker levels, covariates
including age, gender, APOEε4 genotype, BMI, alcohol consumption, smoking, medication use
for cardiovascular diseases, and physical activity were considered in the analysis. Participants
were divided into four groups according to quartiles of nail selenium concentration as Q1, Q2,
Q3 and Q4. The cut off values for selenium were 0.320, 0.467 and 0.568 μg/g.
Analysis of variance, the Kruskal-Wallis test, or chi-squared test was used for univariate
analysis. Unconditional logistic regression models with 0.05 as significance level were used for
multivariate analysis. Separate logistic regression model was used to estimate odds ratios and
95% confidence intervals for the four types of dyslipidemia. We used two models with progres-
sive degrees of adjustment. Model 1 adjusted for age, gender and APOEε4 genotype. Model 2
additionally adjusted for BMI, smoking, alcohol consumption, physical activity and medication
use for cardiovascular diseases. Potential interaction between APOEε4 genotype and selenium
level for the risk of dyslipidemia was also examined in separate models. All analyses were per-
formed using SAS9.1 for Windows (SAS Institute Inc., Cary, North Carolina, USA). P<0.05
was considered statistically significant.
Results
Characteristics of the overall population and in the four groups defined by nail selenium quar-
tile were shown in Table 1. Mean selenium concentration in the overall population was
0.465μg/g with ranges from 0.078 to 4.217 μg/g. Mean selenium concentration of each quartile
group was 0.232, 0.408, 0.516 and 0.705 μg/g, respectively. No difference in age or APOEε4
genotype was observed among the four selenium quartile groups, while significant differences
in the remaining variables were observed.
In the overall population, rates of High-TC, High-LDLC, High-TG and Low-HDLC were
18.13%, 13.23%, 12.21% and 32.76%, respectively, as shown in Table 2. Rates of High-TC,
High-LDLC, High-TG were significantly higher in Q2, Q3 and Q4 groups compared to the Q1
group (p<0.0001), while rate of Low-HDLC in the Q2, Q3 and Q4 groups were significantly
lower (p<0.0001). Compared with APOEε4 non-carriers, rates of High-TC and High-LDLC in
APOEε4 carriers were higher (p<0.0001). Multivariable-adjusted odds ratios of APOEε4 carri-
ers were 1.97(95%CI: 1.46, 2.66) for High-TC and 1.66(95%CI: 1.17, 2.35) for High-LDLC,
respectively. However, no interaction between APOEε4 and selenium level was observed on
the risk of dyslipidemia.
Separate logistic regression analyses indicated that selenium level was significantly associ-
ated with High-TC, High-LDLC and Low-HDLC. Multivariable-adjusted odds ratios for four
types of dyslipidemia with the lowest selenium quartile group(Q1)as the reference group were
calculated using separate logistic models, shown in Table 3. Results indicated that participants
in groups Q2, Q3 and Q4 had higher risk of High-TC and High-LDLC, while participants in
Selenium and Dyslipidemia
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these groups had lower risk of Low-HDLC compared with the Q1 group after adjusting for
other risk factors. Since the confidence intervals for selenium quartile groups Q2, Q3 and Q4
overlap, there were no significant differences in rates of dyslipidemia among these three groups
of individuals. No statistically significant differences were found among the four selenium
quartile groups for High-TG.
Discussion
In this large cross-sectional study in elderly Chinese over the age of 65, we found that selenium
level was associated with dyslipidemia. In particular, participants in higher selenium quartile
groups had higher rates of High-TC, High-LDLC, and lower rate of Low-HDLC compared to
those in the lowest selenium quartile.
Our findings are consistent with published results from other population based studies eval-
uating the relationship between selenium status and the risk of dyslipidemia. A recent case-
control study focusing on the end-point of dyslipidemia found similar results as our study that
selenium levels measured in hair samples were significantly higher in patients with hyperlipid-
emia than those with normal lipid levels [20]. Many studies have focused on the relationship
Table 1. Characteristics of participants by nail selenium quartile groups.
Quartile groups of nail selenium level
Characteristics* Q1(n = 466) Q2 (n = 468) Q3 (n = 462) Q4 (n = 463) Total (n = 1859) P Value
Nail selenium (μg/g) 0.232±0.054 0.408±0.040 0.516±0.029 0.705±0.268 0.465±0.221
Age (years) 73.2±6.0 73.6±6.0 74.1±6.0 74.2±5.7 73.8±5.9 0.0573
Female (%) 43.78 47.86 57.36 65.23 53.52 <0.0001
BMI (kg/m2) 21.75±3.05 22.55±3.74 23.53±3.74 24.53±3.94 23.09±3.78 <0.0001
Alcohol consumer (%) 48.28 41.45 33.12 31.53 38.62 <0.0001
Smoker (%) 39.27 47.65 39.39 32.18 39.64 <0.0001
Medication use (%) 15.24 30.34 36.15 46.44 32.01 <0.0001
APOE ε4 carriers (%) 13.73 18.80 15.80 15.12 15.87 0.1865
Physical activity 0.0086
Low (%) 2.58 4.91 5.21 6.26 4.74
Moderate (%) 13.98 14.74 19.52 16.85 16.26
High (%) 83.44 80.34 75.27 76.89 79.00
* Characteristics were described as mean ± SD or percentages.
doi:10.1371/journal.pone.0136706.t001
Table 2. Rates of four types of dyslipidemia by APOE genotype and by nail selenium quartile groups.
Group N Mean nail selenium (μg/g) High-TC (%) High-LDLC (%) High-TG (%) Low-HDLC (%)
Total 1859 0.465±0.221 18.13 13.23 12.21 32.76
Selenium Quartiles (p-value) <0.0001 <0.0001 <0.0001 <0.0001
Q1 group 466 0.232±0.054 4.94 2.36 6.44 44.21
Q2 group 468 0.408±0.040 20.30 13.25 16.03 30.34
Q3 group 462 0.516±0.029 26.84 18.83 15.80 26.19
Q4 group 463 0.705±0.268 20.52 18.57 10.58 30.24
APOE ε4 status (p-value) <0.0001 0.0089 0.3345 0.8244
APOE ε4 carrier 295 0.465±0.193 27.46 17.97 13.90 32.20
APOEε4 non-carrier 1564 0.465±0.225 16.37 12.34 11.89 32.86
doi:10.1371/journal.pone.0136706.t002
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between blood selenium level and lipid profiles. In selenium-replete populations, positive asso-
ciations of serum selenium with TC, LDLC and TG concentrations were observed [8, 9, 30].
However, the associations were inconsistent in populations with low serum selenium concen-
tration [31–36]. A cross-sectional study in the 2000–2001 UK National Diet and Nutrition Sur-
vey suggested that higher plasma selenium was associated with increased total and non-HDL
cholesterol levels in the UK adult population with lower selenium status [19]. A cohort study
in Finland where selenium levels were among the lowest in the world until the early 1980s
found a positive cross-sectional association between serum selenium status and serum lipids
[21]. However, longitudinal analysis in the same cohort did not support the causality of this
link. Our results, also cross-sectional in nature, will need to be confirmed in future longitudinal
studies.
There has been one randomized trial in elderly volunteers reporting that selenium supple-
mentation resulted in modest reduction in non-HDL cholesterol over a 6-month intervention
period [17]. Interestingly, in the cross-sectional analyses at baseline reported in the RCT trial,
higher plasma selenium was associated with higher total and HDL cholesterol, similar to our
results. However, in longitudinal analyses of this RCT, increasing plasma selenium concentra-
tions from baseline to 6 months were associated with decreasing total cholesterol levels, non-
HDL cholesterol levels, and with increasing HDL cholesterol levels. A potential explanation for
the cross-sectional relationship between higher selenium and higher lipid levels is a shared
enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase, which acts through the mevalo-
nate pathway that affects both selenium and lipids [37]. It has been shown that patients treated
with statins had lower plasma selenium concentrations than patients who did not receive treat-
ment [38]. These results also highlight the necessity for more studies utilizing longitudinal
data.
There were also selenium supplementation trials with cardiovascular disease (CVD) as the
outcome. However, the two largest trials that were conducted in the USA (SELECT and NPC)
found no statistically significant effects of selenium supplementation on CVD events, CVD
Table 3. Multivariable-adjusted odds ratios for four types of dyslipidemia by nail selenium quartile groups.
Dyslipidemia Selenium Q1 group Selenium Q2 group Selenium Q3 group Selenium Q4 group P trend
Reference OR 95%CI OR 95%CI OR 95%CI
High-TC
Model 1 1.00 4.70 (2.91,7.59) 6.52 (4.07,10.44) 4.31 (2.67,6.98) <0.0001
Model 2 1.00 4.51 (2.78,7.30) 6.13 (3.80,9.88) 4.02 (2.45,6.58) <0.0001
High-LDLC
Model 1 1.00 6.03 (3.13,11.65) 8.67 (4.55,16.52) 8.04 (4.21,15.34) <0.0001
Model 2 1.00 5.49 (2.83,10.63) 7.55 (3.93,14.48) 6.48 (3.35,12.51) <0.0001
High-TG
Model 1 1.00 2.76 (1.76,4.32) 2.51 (1.60,3.94) 1.49 (0.92,2.41) 0.3232
Model 2 1.00 2.48 (1.58,3.92) 2.05 (1.29,3.26) 1.12 (0.68,1.85) 0.4956
Low-HDLC
Model 1 1.00 0.55 (0.42,0.72) 0.45 (0.34,0.60) 0.56 (0.42,0.73) <0.0001
Model 2 1.00 0.48 (0.36,0.64) 0.35 (0.26,0.46) 0.38 (0.28,0.51) <0.0001
Model 1: Logistic regression model adjusted for age, gender and APOEε4 genotype. Age was classiﬁed into two groups, the cutoff value was 75. The
reported parameter estimates were odds ratios. Model 2: Additionally adjusted for BMI, smoking, alcohol consumption, physical activity and medication
use for cardiovascular diseases. BMI was classiﬁed into three groups, the cutoff values were 18.5 and 25.
doi:10.1371/journal.pone.0136706.t003
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mortality or all-cause mortality [39–41]. And it is not clear whether lipid levels were different
between the selenium supplement group and the placebo group.
The mechanisms underlying the association between high selenium exposure and lipid
metabolism are not clear, although there are studies suggesting a potential pathway through
oxidative stress. A recent study reported a nonlinear dose-response relationship between
selenium exposure and oxidative stress biomarkers suggesting that higher selenium levels
increased oxidative stress [42]. In addition, there were also findings indicating that selenium
can be identified in human lipoproteins [43] and experimental studies suggesting that selenium
may play an important role in lipid peroxidation and lipoprotein metabolism [14–16,44].
In this study, we found that participants in the top three selenium quartiles had increased
rates of dyslipidemia and the three groups did not differ significantly in rates of dyslipidemia
as indicated by the overlapping confidence intervals for the odds ratio estimates. Our results
seem to point to a threshold effect of selenium levels at the second quartile. However, an
inverse U-shape relationship could also exist between selenium level and dyslipidemia [45], but
we will not be able to detect the downward trend at the very high selenium level from data in
this cohort.
In our study, we also observed that APOEε4 carrier was a significant risk factor for High-
TC and High-LDLC, indicating that genetic factors have a direct effect on cholesterol metabo-
lism. Recent studies on the association between APOE polymorphism and risk of cardiovascu-
lar disease had reached similar conclusions [46–49], and more evidence could be found in
studies on APOE polymorphism and lipid levels [50–53]. On the question of potential interac-
tions between APOE genotype and selenium level for the development of dyslipidemia, animal
studies demonstrated that selenium supplementation was responsible for down regulation of
apoB expression during hypercholesterolemia [54, 55], and could increase the LDL-receptor
activity [56,57]. Analysis of plasma proteins in Trsp knockout mouse revealed increases in
apolipoprotein E level accompanied with elevated plasma cholesterol levels, providing the first
evidence that selenoproteins may play a role in regulating lipoprotein biosynthesis and metab-
olism [58]. Although associations between selenium level and APOE genotype were found in
population based studies [25, 59], we found an independent association of selenium and APOE
on the risk of dyslipidemia in the present study.
For the general population, the primary pathway of exposure to selenium is food, followed
by water and air [60]. Selenium content in foods varies greatly depending on the selenium con-
tent of the soil where plants are grown while up to 10-fold differences in selenium contents can
be found in the same food item [61]. Dietary selenium is found to be highly bioavailable and its
elimination in humans was shown to be in three phases with the last phase lasting as long as
200 days [62]. Nail selenium was used as the biomarker to measure individual selenium expo-
sure in our study for two reasons: nail samples were believed to provide an accurate measure of
long-term exposure to selenium [62] and nail selenium measures are stable and do not fluctu-
ate greatly with daily selenium intake in the diet [63]. In a previous study of the same cohort
[23], we have confirmed that nail selenium levels were significantly correlated with selenium
levels measured in blood, food samples and dietary intake derived from food frequency ques-
tionnaire. Positive correlations between nail selenium and selenium in urine, whole blood and
serum were also confirmed in other studies [64–66]. However, since in this study hair samples
were not collected, a reliable comparison between our observations and results on selenium
measured in hair samples is not available.
Selenium levels in various cohorts differ by the geographic locations of the study population
[67]. Although US cancer studies reported mean nail selenium levels of 0.8 μg/g in control sub-
jects, European cohorts included many control groups with nail selenium levels around 0.5 μg/
g, overlapping with the selenium range in our cohort. It is worth noting that the selenium levels
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reported in cohorts from developed countries may also be influenced by dietary supplements
and, hence, may not be reflective of lifelong exposure. Recommended daily selenium intakes
were established to maximize plasma glutathione peroxidases activity [68]. However, it remains
to be seen whether these recommended levels are optimal for various health outcomes.
Our study has a number of strengths. The first is the relatively large sample size ensuring
adequate statistical power. The second is the relatively low selenium level in the study popula-
tion without selenium supplementation, which provided an opportunity to explore the associa-
tions between selenium exposure and dyslipidemia risk. The third is selenium measurements
in nail samples, which provided a relatively long-term measure of exposure compared with
selenium measured in blood or urine samples. For life-long rural residents consuming local
food, nail selenium level closely reflects life-long selenium exposure level [62].
Our study is limited by its cross-sectional design and the results are subject to the bias of
reverse causation. Longitudinal studies will be needed to confirm our results. In addition, our
study result is limited to subjects older than 65 years of age. Therefore, it is not known whether
the association between selenium level and the risk of dyslipidemia holds in populations of
younger subjects. Furthermore, only APOE genotype was examined in the present study. Addi-
tional genetic and environmental confounders should be explored for the better understanding
of the relationship between selenium level and dyslipidemia.
In summary, our results suggest long-term selenium higher exposure level may be associ-
ated with the risk of dyslipidemia in the elderly population. Future studies are needed to con-
firm our findings and to examine the underlying mechanism of the association.
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